Revenue 470 billion yen (YoY +17.5%), operating income 41.4 billion yen (YoY +20.4%), core operating income 43.1 billion yen (+28.6%), driven by growth of the three key 3L products. Full-year forecast: revenue 883.5 billion yen, operating income 70.0 billion yen, with progress rates of 53.2% and 59.2% respectively.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4523-20261110-03.pdf","jir_short_summary":"Revenue 470 billion yen (YoY +17.5%), operating income 41.4 billion yen (YoY +20.4%), core operating income 43.1 billion yen (+28.6%), driven by growth of the three key 3L products. Full-year forecast: revenue 883.5 billion yen, operating income 70.0 billion yen, with progress rates of 53.2% and 59.2% respectively.","jir_summary":"### Summary of Results\nPharmaceutical operations expanded significantly this period, led by growth of the 3L products (LENVIMA, DAYVIGO, LEQEMBI). Revenue reached 470 billion yen (YoY +17.5%), operating income was 41.4 billion yen (+20.4%), and core operating income was 43.1 billion yen (+28.6%), achieving double-digit profit growth. Contributions from key products supported solid growth across multiple global markets.\n\n### Outlook and Impact for Investors\nThe full-year forecast is revenue of 883.5 billion yen and operating income of 70.0 billion yen, with progress at 53.2% and 59.2% respectively. Growth centered on the 3L franchise is expected to continue, particularly in the U.S., Japan, and China where new indications and launches are progressing. For investors, the growth foundation established in H1 FY2026 is solid, and further contributions to results are anticipated in H2 and beyond.","jir_financial_highlights":"Revenue: 4,700 (Year-over-Year +17.5%)\nOperating Income: 414 (Year-over-Year +20.4%)\nCore Operating Income: 431 (Year-over-Year +28.6%)\nNet Income Attributable to Owners of Parent: 299 (Year-over-Year +21.5%)\nEPS (yen): 106.18 (Year-over-Year +21.5%)\nFull-Year Forecast Revenue: 8,835 (Progress Rate 53.2%)\nFull-Year Forecast Operating Income: 700 (Progress Rate 59.2%)","jir_category":"","jir_hashtags":"#Eisai, #Earnings, #BusinessGrowth, #3L, #PharmaceuticalBusiness","jir_key_figures":"Revenue: 4,700 (hundred million yen) Year-over-Year +17.5%\nOperating Income: 414 (hundred million yen) Year-over-Year +20.4%\nCore Operating Income: 431 (hundred million yen) Year-over-Year +28.6%","jir_meta_title":"Eisai Co., Ltd. FY2026 Q2 Results | Revenue 470 billion yen, Operating Income 41.4 billion yen, Growth Driven by 3L","jir_meta_description":"Overview of Eisai Co., Ltd.'s FY2026 Q2 results: revenue 470 billion yen (YoY +17.5%), operating income 41.4 billion yen, core operating income 43.1 billion yen. Full-year forecast: 883.5 billion yen revenue and 70.0 billion yen operating income, driven by growth of the 3L franchise.","jir_og_title":"Eisai Co., Ltd. Announces Q2 Results | Revenue 470 billion yen, Double-Digit Profit Growth","jir_og_description":"Eisai Co., Ltd.'s FY2026 Q2 results: strong pharmaceutical growth led by 3L contributions. Full-year forecast 883.5 billion yen revenue and 70.0 billion yen operating income, progress at 53% and 59%.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q4\\\",\\\"2026 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4000,4700]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q4\\\",\\\"2026 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[344,414]}]}}\"}, {\"jir_chart_id\": \"core_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q4\\\",\\\"2026 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income\\\",\\\"data\\\":[335,431]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Americas\\\",\\\"China\\\",\\\"EMEA\\\",\\\"EAGS\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Pharmaceutical Revenue\\\",\\\"data\\\":[~1500,~1800,~800,~440,~400,~79]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gross Margin\\\",\\\"Operating Margin\\\",\\\"Core Operating Margin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Rate\\\",\\\"data\\\":[54.2,8.8,9.2]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Apr-Sep Actuals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Full-Year Forecast vs Actual\\\",\\\"data\\\":[53.2]}]}}\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147178","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n